Hormone therapy in breast and prostate cancer

V. Craig Jordan, B.J.A. Furr0896036731, 9780896036734

Northwestern Univ., Chicago, IL. Presents a review of the endocrine treatment of breast and prostate cancer by the originators, a model for making new discoveries in the chemoprevention of cancer, a synthesis of history and clinical practice, and a guide for progress. DNLM: Breast Neoplasms–drug therapy.

---

Table of contents :
ASD ZONE……Page 1
CONTENTS……Page 12
1 An Introduction to the Regulation of Sex Steroids for the Treatment of Cancer……Page 18
Part I: Preclinical Antiestrogens……Page 31
2 Antiestrogens and the Cell Cycle……Page 32
3 Drug Resistance to Antiestrogens……Page 61
4 Mechanisms of Liver Carcinogenesis by Antiestrogens……Page 83
5 The Effects of Triphenylethylene Antiestrogens on Parameters of Multistage Hepatocarcinogenesis in the Rat……Page 96
6 Preclinical Studies of Raloxifene and Related Compounds……Page 145
7 Pure Antiestrogens……Page 172
Part II: Antiestrogens: Clinical……Page 193
8 Tamoxifen for the Treatment of Breast Cancer……Page 194
9 Clinical Utility of New Antiestrogens……Page 203
10 Breast Cancer Prevention with Antiestrogens……Page 221
Part III: Inhibition of Estrogen Synthesis……Page 240
11 Aromatase Inhibitors……Page 241
12 Clinical Utility of Aromatase Inhibitors……Page 270
13 LH-RH Agonists for the Treatment of Breast Cancer:……Page 297
Part IV: Androgens and Androgen Withdrawal……Page 313
14 Molecular Action of Androgens……Page 314
15 Steroidal Antiandrogens……Page 328
16 Nonsteroidal Antiandrogens……Page 350
17 LH-RH Agonist Role in Prostate Cancer Management……Page 372
Part V: Perspective on Progress……Page 386
18 Recent Progress in Breast Cancer Research……Page 387
Index……Page 411